Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ANDA Filing Free-For-All? Matrix's Stay In Kaletra Case Could Remove Risks Of Submitting Early Dual Certification Generic Drug Applications

Executive Summary

Matrix's ability to win a stay of litigation over Kaletra patents - and thus avoid a potential forfeit of its generic exclusivity - suggests a possible strategy for other early ANDA filers

You may also be interested in...



Generics Industry Faces Five Major Challenges, Actavis CEO Says (We're Partly Responsible For One Of Them, He Acknowledges)

U.S. ANDA makers are ending their silver anniversary year on a glum note

Generics Industry Faces Five Major Challenges, Actavis CEO Says (We're Partly Responsible For One Of Them, He Acknowledges)

U.S. ANDA makers are ending their silver anniversary year on a glum note

Teva Gets Exclusivity For Generic Kytril; FDA Still Worries About Racing, Parking

In granting Teva 180-day marketing exclusivity for its generic formulation of Roche's antinausea drug Kytril (granisetron), FDA has laid out initial ground rules for determining when ANDA holders forfeit exclusivity

Topics

UsernamePublicRestriction

Register

MT125529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel